|
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
|
Recognizing the Substantial Burden of Alopecia in Pediatric Patients and Building Multidisciplinary Capacity and Competence to Address Unmet Needs
Hair loss can have a profound psychological impact, especially on adolescents who may face social stigma or have self-esteem issues. Accurate diagnosis and appropriate management in this patient population can improve not only physical symptoms but also mental well-being.
If you’re a clinician who treats alopecia areata (AA) in pediatric patients, take your skills to the next level by accessing ACHL’s AdaptED® platform, which offers a tailored learning experience for busy clinicians, ... |
|
|
Tackling Chronic Inflammatory Airway Diseases A Unified Picture of Disease Processes and Targeted Management
Chronic inflammatory diseases of the upper and lower airways, including allergic rhinitis, CRSwNP, and asthma, have been tied to significant risks and burdens for affected patients. Although biologic therapies that target overactive cytokine signaling are available, newer therapies are emerging, with targets upstream in the pathogenic cascade to improve efficacy across both T2-high and T2-low profiles. Join us for this engaging Expert Roundtable™ activity to hear multidisciplinary insights r... |
|